1,6-naphthyridine derivatives as CDK4/6 inhibitor
US10676474B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 15, 2017 |
| Grant date | Jun 9, 2020 |
| Priority date | — |
| Expiry date | Dec 15, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/4965
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a series of compounds acting as CDK4/6 inhibitors. Specifically disclosed are compounds as represented by formula (I), pharmaceutically acceptable salts or isomers thereof, pharmaceutical compositions containing same, and the use thereof in the preparation of drugs for treating cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.